|
|
Articles
by
H. Robert Brashear |
Total Records (
2 ) for
H. Robert Brashear |
|
 |
|
|
|
Reisa A. Sperling
,
Clifford R. Jack
,
Sandra E. Black
,
Matthew P. Frosch
,
Steven M. Greenberg
,
Bradley T. Hyman
,
Philip Scheltens
,
Maria C. Carrillo
,
William Thies
,
Martin M. Bednar
,
Ronald S. Black
,
H. Robert Brashear
,
Michael Grundman
,
Eric R. Siemers
,
Howard H. Feldman
and
Rachel J. Schindler
|
|
Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-β burden in Alzheimers disease (AD). In response to concerns raised by the Food and Drug Administration, the Alzheimers Association Research Roundtable convened a working group to review the publicly available trial data, attempts at developing animal models, and the literature on the natural history and pathology of related conditions. The spectrum of ARIA includes signal hyperintensities on fluid attenuation inversion recoverysequences thought to represent vasogenic edema and/or sulcal effusion (ARIA-E), as well as signal hypointensities on GRE/T2∗ thought to represent hemosiderin deposits (ARIA-H), including microhemorrhage and superficial siderosis. The etiology of ARIA remains unclear but the prevailing data support vascular amyloid as a common pathophysiological mechanism leading to increased vascular permeability. The workgroup proposes recommendations for the detection and monitoring of ARIA in ongoing AD clinical trials, as well as directions for future research. |
|
|
|
|
Maria C. Carrillo
,
H. Robert Brashear
,
Veronika Logovinsky
,
J. Michael Ryan
,
Howard H. Feldman
,
Eric R. Siemers
,
Susan Abushakra
,
Dean M. Hartley
,
Ronald C. Petersen
,
Ara S. Khachaturian
and
Reisa A. Sperling
|
|
Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD. |
|
|
|
|
|
|